Ivermectin
Ivermectin is an FDA-approved antiparasitic agent (1996) with an established three-decade safety record at standard antiparasitic dosing (150–200 mcg/kg, typically given as a one- or two-time dose for strongyloidiasis or onchocerciasis). Off-label use in cancer settings is based on preclinical evidence of multi-target activity — including PAK1 inhibition, Wnt/β-catenin pathway suppression, P-glycoprotein inhibition, microtubule disruption, and induction of mitochondrial apoptosis — demonstrated in cell-line, organoid, and animal models. Clinical evidence in humans remains extremely limited: a single ongoing phase I/II trial at Cedars-Sinai is studying ivermectin combined with anti-PD-1 therapy in metastatic triple-negative breast cancer, with no treatment-related serious adverse events reported among the first nine patients; an additional academic trial opened at the University of Florida in 2026. No completed randomized controlled trial supports antitumor efficacy. The 2026 Hulscher and colleagues observational cohort in Anticancer Research — the most widely circulated "clinical" evidence in the patient information environment, reporting 84.4% clinical benefit at six months — is the subject of a formal post-publication audit initiated by the publishing journal to verify IRB approval, source-confirm the baseline cancer diagnoses of the 197 enrolled patients, and document the reported anatomical regressions; an Expression of Concern remains appended to the article during this audit. A 2025 gynecologic oncology review concluded with a strong recommendation against off-label ivermectin use outside clinical trials.
Clinical Alerts
Drug Interactions
Hepatotoxicity EVIDENCE EMERGING
Liver enzyme elevation is documented in case literature, particularly at higher cumulative doses and in protocols that stack ivermectin with mebendazole or fenbendazole. NIH LiverTox lists ivermectin as a likely rare cause of clinically apparent liver injury. The popular FLCCC/TWC protocol prescribes ivermectin and mebendazole together for months, which compounds hepatic exposure beyond what either agent has been individually studied for. Check LFTs at baseline and every 4–6 weeks for any patient on a sustained high-dose protocol; ask about supplement and protocol use in patients with unexplained transaminitis.
Formulation & Source
Three distinct sources circulate: FDA-approved pharmaceutical ivermectin (3 mg tablets, prescription); compounded ivermectin (commonly via telehealth platforms — The Wellness Company, FLCCC-affiliated networks — typically as ivermectin–mebendazole combination capsules); and veterinary formulations (1.87% paste, injectable solutions, pour-on products) marketed for livestock. As of 2025, several states (Arkansas, Idaho, Tennessee, New Hampshire) have authorized over-the-counter pharmaceutical ivermectin sales. Ask which product the patient is using and at what dose; veterinary products carry unknown excipients and dose-by-volume rather than dose-by-weight.
Strongyloides Screening
Patients with epidemiologic risk for Strongyloides stercoralis (residence or extended travel in tropical or subtropical regions, including the rural U.S. South) who are about to receive corticosteroids, checkpoint inhibitors, or other significant immunosuppression are at risk for hyperinfection syndrome (mortality 10–50%). Standard antiparasitic-dose ivermectin (200 mcg/kg) is the appropriate empiric treatment. This is a legitimate, evidence-based use of ivermectin in the oncology population and is distinct from the off-label cancer-protocol context.
Patient Information Environment
How ivermectin became a cancer narrative: Ivermectin is not a traditional complementary or alternative therapy. It is an FDA-approved prescription pharmaceutical whose off-label cancer use was constructed almost entirely after 2020, emerging from the COVID-19 information ecosystem. Patients arrive at ivermectin via a distinct pipeline: politicized media (Joe Rogan, Tucker Carlson, and a broader podcast ecosystem in the wellness-right and "medical freedom" space), celebrity testimony (Mel Gibson's 2025 podcast claim that ivermectin and fenbendazole cured stage IV cancer in three of his friends), dedicated telehealth platforms with active MD prescribers, and a small set of physician advocates (Pierre Kory, Peter McCullough, Paul Marik, William Makis, Drew Pinsky). Disclosure data are limited; a 2023 cross-sectional study in Loja, Ecuador found 19% of survey respondents reported using ivermectin as a cancer-treatment adjunct. U.S. disclosure rates are unmeasured but likely depressed by patients' anticipation that the oncologist will object on political rather than clinical grounds. A clinically significant share of ivermectin-using cancer patients have an active prescribing relationship with an MD-credentialed telehealth provider. This is structurally a parallel-provider situation, but the credential calculus differs from naturopathy: the parallel provider holds an MD and DEA registration, which means appeals to credential authority will not move the patient and may damage the conversation.
Misinformation environment: The ivermectin-for-cancer narrative is younger, more politically charged, and more institutionally organized than most cancer-misinformation environments. Its central rhetorical move is the suppression frame: ivermectin is positioned as a cheap, off-patent, Nobel-Prize-winning drug that pharmaceutical companies and regulators have actively buried to protect oncology revenues, a frame given continuity by the COVID-19 history that preceded it. Patient interest is sustained by a coordinated telehealth pipeline — The Wellness Company (TWC), founded in 2022, sells a compounded ivermectin–mebendazole combination through its licensed U.S. providers, with patient-facing visibility built around Peter McCullough and Drew Pinsky; the Front Line COVID-19 Critical Care Alliance (FLCCC, led by Pierre Kory and Paul Marik) operates a parallel referral network with affiliated prescribing physicians, and William Makis publishes regularly escalating dose protocols on Substack. The most-cited "clinical" evidence is the 2026 Hulscher and colleagues paper in Anticancer Research, an observational cohort drawn from TWC clientele — published by authors all affiliated with TWC, and now under formal Expression of Concern from the publishing journal. For a meaningful subset of patients, ivermectin use functions as a marker of identity and alignment with a broader anti-establishment medical community; for others, it is a purely pragmatic "throw everything at the wall" calculation made under existential pressure. The clinical conversation needs to work for both, without assuming either.
What patients are encountering online:
- The FLCCC ivermectin–fenbendazole–mebendazole "I-FM" cancer protocol (Marik and colleagues, 2024)
- William Makis Substack protocols with dose escalation to 1 mg/kg/day for "aggressive" or "turbo cancer" presentations
- The Wellness Company's compounded ivermectin–mebendazole product, marketed through Drew Pinsky and Peter McCullough
- The Hulscher 2026 Anticancer Research paper cited as "peer-reviewed clinical evidence" of 84% clinical benefit, typically without the journal's Expression of Concern
- Mel Gibson's 2025 podcast claim that ivermectin and fenbendazole cured stage IV cancer in three of his friends
- The 2025 Makis, Baghli & Martinez fenbendazole case series in Case Reports in Oncology claiming three stage IV remissions — formally retracted by the journal in 2026 but still widely circulated
- Joe Rogan Experience, Tucker Carlson, and adjacent podcasts amplifying suppression narratives ("the Nobel Prize–winning drug they don't want you to take")
- "Cancer is a parasite" pseudo-mechanistic framing used to justify antiparasitic protocols
- "Turbo cancer" narratives connecting cancer recurrence or new diagnosis to COVID-19 vaccination, with ivermectin positioned as the remedy
- Veterinary ivermectin (1.87% horse paste, pour-on, injectable) dose-calculator tutorials on TikTok, Reddit, and Telegram
- Substack newsletters from Kory, McCullough, and Makis with regularly updated dose protocols
How did the patient raise this?
Select the appropriate scenario.
Exploratory Inquiry or Family Pressure
"My brother keeps sending me articles about ivermectin for cancer. He's pretty insistent. What do I tell him?"
Curative Intent or Already Started, Still in Treatment
"I've been reading about how ivermectin starves cancer cells. Have you seen the studies?"
Stopped, Replacing, or Replacing-Adjacent Treatment
"I'm going to stop chemo and do the FLCCC protocol instead."
Scenario A: Communication Guidance
Your task
The patient has not committed to ivermectin and is bringing it into the room as a question rather than a decision. The task is to take the inquiry seriously, get a clear picture of where they are in the information environment, and keep the door open for future disclosure.
What to watch for
Dismissing the question on political or cultural grounds — even subtly, through tone — typically ends both the present conversation and the next one. The ivermectin question rarely arrives without the patient already anticipating that the oncologist will object on something other than clinical grounds. A flat "no, that's misinformation" confirms the framing the patient has been primed to expect and shifts a future yellow- or red-zone conversation into territory the clinician can no longer reach.
Opening the conversation
Start by asking what they've encountered and from whom. The ivermectin pipeline is structured — celebrities, podcasts, family members, specific telehealth platforms — and naming what the patient has actually been exposed to is more useful than treating it as generic curiosity.
Key strategies
Distinguish exploratory interest from family pressure: These are different conversations. A patient who is curious wants information. A patient who is being lobbied by a family member wants language to bring back to that conversation. Ask which it is. For family pressure: "It sounds like the harder thing here might be the conversation with your brother. Would it help if we talked about how you want to handle that?"
Be specific about the evidence state: Research shows that detailed, specific information is more effective than generic warnings. For ivermectin, the honest answer is that there are real preclinical findings (PAK1, Wnt, microtubule, P-gp), one ongoing phase I/II trial at Cedars-Sinai, and no completed clinical trial in humans showing ivermectin treats cancer. Name that gap directly rather than collapsing it into "no evidence."
Keep the door open for disclosure: The most important outcome of this conversation is that the patient tells you if they start the protocol later. "If you do decide to try it, I want to know — not to argue with you, but because there are real interactions and side effects I need to track."
Orient toward reliable sources: Memorial Sloan Kettering's About Herbs database, NCI PDQ, and ClinicalTrials.gov for the active ivermectin oncology trials are appropriate patient-facing references. The Anticancer Fund has a balanced patient-facing explainer on repurposed drugs that takes the question seriously rather than dismissing it.
⚑ If the patient mentions a specific high-dose protocol (FLCCC, Makis, TWC): Flag the dosing now, even before anything is started. "The standard antiparasitic dose is one or two single doses of about 12 milligrams. The protocols you've been reading about use 25 milligrams a day for months, and some go to 1 milligram per kilogram daily, which can be 70 milligrams or more. That's a different drug at that exposure — different side effect profile, different neurologic risk. I'd want to walk through that with you before anything starts."
Scenario B: Communication Guidance
Your task
The patient is still engaged with their treatment and still talking to you. The goal of this conversation is not to correct their information in a single visit — it is to ensure they continue bringing you information across future visits, and to flag the specific clinical risks that change because of what they're doing.
What to watch for
Research shows that immediately correcting a patient's misinformation before understanding their reasoning reduces engagement and makes the patient less likely to raise concerns in future visits. For ivermectin specifically, the patient has typically already anticipated a dismissive response — that anticipation is part of why disclosure took as long as it did. The conversation that feels most clinically urgent — "I need to set them straight about Joe Rogan" — is the one most likely to close the door for the next eight months of treatment.
Opening the conversation
Before correcting, find out what the patient believes, where it came from, and why they find it compelling. Research on motivated reasoning shows that resistance to scientific information is rarely about not having the facts — it is driven by underlying fears, identity, worldview, or distrust of institutions. For ivermectin, the underlying driver is unusually likely to involve distrust formed during COVID-19 and a community of trusted sources who provide a coherent alternative explanation. A correction that ignores the underlying motivation will fail.
Key strategies
Identify what's actually driving the interest: For ivermectin, the surface claim ("ivermectin treats cancer") is rarely the real motivation, and correcting only the surface claim almost never holds. The underlying drivers tend to cluster into a small set of patterns, each of which calls for a different response. Naming which pattern is operating early in the conversation is more useful than working through them generically.
If the patient is positioning ivermectin as part of a broader rejection of pharmaceutical medicine — typically formed during or after COVID-19 — repeating clinical evidence from the institutions that lost their trust will not work and will likely make things worse. The trust position has to be acknowledged before any clinical content lands. "It sounds like some of this is about ivermectin, but a lot of it is about not trusting the institutions I'm part of. I want to take that seriously, not work around it."
If the patient is reasoning from existential pressure — aggressive disease, prognosis worse than they wanted — the ivermectin interest is partly a "throw everything at the wall" calculation, and the response is different from a trust-driven case. "I hear that you want to do everything possible. I want that too. Let me be direct about what we know works for your specific cancer and what's not yet known to work, so the things you add are additive and not subtractive."
If the patient is being lobbied by family, a partner, or an online community they value, the conversation in the room is not actually between you and the patient — it is between you and the absent third parties, with the patient as messenger. Language the patient can take back to those conversations may matter as much as language for the visit itself.
If the patient identifies specifically with a physician advocate (Kory, McCullough, Makis) or a telehealth network, you are not just correcting information — you are entering a competing clinical relationship. Treating that prescriber as a clinical second opinion rather than as a misinformation source to discredit is both more accurate and more effective; the dismissive frame typically aligns the patient more tightly with the prescriber.
Offer a detailed alternative explanation: Research shows that corrections work significantly better when they explain why the misinformation seems credible rather than simply negating it. For ivermectin, the patient has typically encountered three layers: real preclinical findings (PAK1, Wnt signaling, P-gp inhibition); the observational cohort claiming 84% clinical benefit; and a coherent suppression story explaining why mainstream oncology has not adopted it. Address each layer rather than the surface claim.
Engage the suppression narrative directly, briefly, and without defensiveness: The "Big Pharma is suppressing a cheap repurposed drug" frame is the most rhetorically powerful piece of the ivermectin information environment. Refusing to engage it reads as confirmation. The honest counter is short: cheap, off-patent, repurposed drugs are studied all the time, including by NIH and academic centers (metformin, aspirin, statins in cancer prevention are working examples), and the most prominent ivermectin–cancer "trial" available to the patient is being run by the same telehealth company selling the protocol. "I can't speak to everything the pharmaceutical industry does. What I can tell you is that the people most loudly claiming suppression are also the ones selling the protocol. That's worth noticing."
Address the parallel prescriber without disparaging: If the ivermectin came from a telehealth provider, the patient has an active clinical relationship with a credentialed MD whose framing of the situation differs from yours. Pulling the patient toward your authority by attacking the other provider typically backfires and confirms the "establishment vs. dissident doctors" frame the patient has been primed to expect. Stay specific to this patient's cancer and this patient's treatment regimen. "Your other prescriber is reasoning from general protocols. I'm reasoning from your pathology, your stage, your specific regimen, and your specific labs. That's where I want to focus."
Help them evaluate future claims: Was this a study in humans or in cells? Was there a control group, or was it patient self-report? Who funded it, and was the journal that published it concerned about the data afterward? Does the source sell the protocol they're recommending?
Plan to revisit: Corrected beliefs are fragile and vulnerable to re-exposure, particularly when the patient remains embedded in an information ecosystem actively producing reinforcing content. Keep the door open: "Let's keep talking about this. New things will come at you. I want to know what you're reading, and I want you to know what I'm seeing on the clinical side."
⚑ If the patient is on a high-dose protocol (FLCCC, Makis, TWC): The protocols circulating prescribe 25 mg daily, six or seven days a week, with some recommending escalation to 1 mg/kg/day. Standard antiparasitic dosing is 150–200 mcg/kg given once or twice. The cancer-protocol dose is roughly 25–50 times standard cumulative exposure over months. Notably, the same Hulscher 2026 cohort that patients cite for efficacy also documented neurological symptoms in roughly 13% of the patients who reported side effects — a signal consistent with what would be expected at supratherapeutic doses. "I want to flag the dose itself, separate from the cancer question. At the doses these protocols use, the neurotoxicity signal is real — encephalopathy, ataxia, confusion. Even the study patients use to argue this is safe reported neurological symptoms in a meaningful percentage of users. If you continue this, I'd want LFTs at baseline and every six weeks, and I want you to call immediately if you have new confusion, balance problems, or vision changes. Do you know what dose you're actually taking?"
Scenario C: Communication Guidance
Your task
The patient has decided to stop, reduce, or replace conventional treatment in favor of an ivermectin-based protocol. Maintaining the therapeutic relationship is the clinical priority, because re-engagement with treatment, if it happens, will come through that relationship. The conversation is also unusually likely to involve political and identity content; the clinical task is to engage that content factually rather than dismissively while keeping the focus on this specific patient's cancer.
What to watch for
Research on psychological reactance shows that leading with clinical authority when a patient has already made an autonomous decision — expressing alarm, disappointment, urgency, or moral judgment — typically entrenches the position rather than opening it to reconsideration. For ivermectin specifically, two additional reactance risks compound this: (1) the patient has often anticipated a confrontational response and may have rehearsed counter-arguments before the visit; (2) the political or identity dimension means that a dismissive tone can register not just as professional disagreement but as an attack on the patient's community and worldview. The more pressure the patient feels, the more aligned they become with the alternative-medical community offering the protocol.
Opening the conversation
The misinformation has already produced a behavioral outcome — the patient has altered or abandoned treatment. Research suggests that beliefs become harder to revise when they are reinforced by identity, autonomy, and prior decisions. For ivermectin, the entanglement is unusually thick: the protocol has typically been chosen alongside a specific community of trusted sources, a specific prescribing relationship, and often a broader stance toward medical institutions formed during COVID-19. Start by understanding the patient's reasoning, including the parts that aren't strictly clinical, before attempting to address it.
When you discuss the evidence
The patient has acted on the belief that ivermectin — usually in combination with mebendazole or fenbendazole, on a protocol from FLCCC, William Makis, or TWC — can treat their cancer. The corrections that typically matter are: (1) the preclinical-to-clinical gap (cell-line and animal findings have not translated to demonstrated human treatment efficacy); (2) the absence of completed RCTs against the abundance of observational and preclinical "evidence"; (3) the specific provenance of the most-cited evidence (the observational cohort circulating as 84% clinical benefit was drawn from the telehealth company's own clientele, published by authors all affiliated with that company, and is under formal Expression of Concern from the publishing journal); (4) for any patient still considering reversal — the specific outcome data for their cancer if treatment is resumed versus the absence of outcome data for the alternative. Correcting these now also means telling the patient that the basis for a major life decision was flawed. Engage the evidence only when the patient is open to it, and anchor it to their specific situation rather than to the general claim.
Key strategies
Acknowledge legitimate grievance without conceding the clinical claim: Research on correcting politically charged health misinformation shows that narrative correctives that acknowledge the legitimate basis of distrust outperform didactic corrections, particularly for moderate and conservative audiences. Public health did make mistakes during COVID-19 — shifting mask guidance, school closure debates, lab-leak dismissal — and pretending otherwise destroys credibility instantly. Acknowledging this is a precondition for being heard, not a concession. "I'm not going to defend everything public health did during COVID. Some of it was wrong. The question I want to ask is whether the people who got that story right are the right people to listen to about your specific cancer."
Explore ambivalence — particularly around the prescriber relationship: Motivational interviewing theory holds that patients facing major health decisions typically suppress one side of their ambivalence rather than resolving it. Questions that surface the suppressed side are more likely to produce movement than corrections. General openings: "What would change your mind?" or "What worries you most about your current plan?" For ivermectin specifically, ambivalence often clusters around the telehealth prescriber and the financial structure of the protocol: "What did your prescriber say would happen if you stopped chemotherapy entirely? Did they recommend that?" or "If you knew the people running the most-cited study were also the people selling the product, would that change anything for you?"
Be concrete and specific — name the evidence asymmetry: Research on misinformation correction consistently shows that detailed, specific explanations are more effective than general warnings. For ivermectin, the asymmetry is sharper than "the research is mixed" — for the patient's recommended treatment, outcome numbers exist because pivotal trials were completed. For the ivermectin protocol as cancer monotherapy, those numbers do not exist because no controlled trial has ever been completed. The patient has not been told "no" by science. They have been told "we don't know" by the absence of science, and that absence has been filled by a coordinated narrative.
Treat the parallel prescriber as a second opinion, not as a collaborator: The patient typically has an active prescribing relationship with an MD-credentialed telehealth provider who has framed the situation differently than you have. The credential asymmetry that often shapes naturopath conversations does not apply — disagreeing on the basis of "I'm an oncologist and they're not" is structurally available but practically ineffective. The disagreement is between two MDs reasoning from different evidence standards, with the patient in the middle. Don't disparage the other prescriber. Locate the disagreement in oncology-specific expertise: "Your other prescriber is reasoning from a general protocol that's supposed to work across most cancers. I'm reasoning from your specific pathology, your specific stage, and the trial data for your specific situation. Those are different reasoning frameworks, and for your cancer, the second one is the one with outcome numbers attached to it."
Address what's underneath: A patient who has left treatment for an ivermectin protocol has typically done so for reasons beyond the ivermectin claims themselves — fear of chemotherapy side effects, distrust of pharmaceutical medicine, identity alignment with an anti-establishment medical community, experiences of being dismissed by previous providers, financial burden of conventional treatment, or a need for agency in a situation that otherwise feels passive. If the driver is distrust formed during COVID, repeating clinical evidence from large institutions will not work. If it is fear of specific side effects, discussing side effect management may matter more than discussing efficacy. If it is a need for agency, naming what the patient can actively do alongside conventional treatment may displace some of the ivermectin pull. The correction must engage the actual driver, not just the surface claim.
Respect autonomy without abandoning your clinical perspective: Respecting patient autonomy does not mean agreeing with the patient's decision — it means ensuring the decision is fully informed. You can be direct about the clinical stakes while respecting the patient's right to decide. The MI principle "clarify and accept" applies here: name the decision back to the patient with full information, and accept that it is theirs to make.
Schedule follow-up regardless of outcome: "Whatever you decide, I'd like to see you in [timeframe]. We can talk about how things are going." This communicates that the relationship is not contingent on treatment compliance. Research shows that sustained engagement — even without immediate behavior change — increases the probability of eventual change, particularly when the patient encounters disease progression on the alternative protocol and needs somewhere to return that is not preconditioned on contrition.
Involve the care team: If the patient has stopped curative-intent treatment, document the conversation and notify the broader care team. Consider whether social work, palliative care, patient navigation, or psycho-oncology should be involved — not to pressure the patient, but to ensure support is available. For patients on sustained high-dose ivermectin or ivermectin–mebendazole protocols, baseline LFTs and a low threshold for re-evaluation of neurologic symptoms are reasonable regardless of the cancer-treatment status. Where available, an in-house integrative oncology consult can engage the alternative protocol on its specifics rather than dismissing it as a category.
⚑ If the patient is on a high-dose protocol: The neurotoxicity considerations apply regardless of whether the patient ultimately returns to conventional treatment. "Separate from the cancer question, I want to track what's happening to you on the ivermectin itself. The dosing in these protocols is far above what the safety profile was built on, and the neurotoxicity signal — encephalopathy, ataxia, confusion — is real. I'd want LFTs at baseline and every six weeks, and I want you to call me immediately if you have new balance problems, vision changes, or confusion. That's true whether or not you continue the protocol, and it's true whether or not you come back to chemo." Framing the monitoring as care for the patient's chosen path rather than as a wedge for treatment-resumption preserves the relationship and protects the patient from the highest-acuity risk of the protocol.